Lung cancer is a leading cause of
cancer-related mortality worldwide, with
non-small cell lung cancer (NSCLC) being the most common histological type. Owing to the limited therapeutic efficacy and side effects of currently available
therapies for NSCLC, it is necessary to identify novel therapeutic targets for NSCLC. Long non-coding RNAs (lncRNAs) are non-
protein-coding RNAs with a transcript length of more than 200
nucleotides, which play a vital role in the
tumorigenesis and progression of multiple
cancers, including NSCLC. Induction of programmed cell death (PCD) is the main mechanism leading to tumour cell death in most
cancer treatments. Recent studies have demonstrated that lncRNAs are closely correlated with PCD including apoptosis, pyroptosis, autophagy and ferroptosis, which can regulate PCD and relevant death pathways to affect NSCLC progression and the efficacy of clinical
therapy. Therefore, in this review, we focused on the function of lncRNAs in PCD of NSCLC and summarized the therapeutic role of targeting lncRNAs in PCD for NSCLC treatment, aiming to provide new sights into the underlying pathogenic mechanisms and propose a potential new strategy for NSCLC
therapy so as to improve therapeutic outcomes with the ultimate goal to benefit the patients.